Prognostic implications of microRNA-21 overexpression in invasive ductal carcinomas of the breast

Journal of Breast Cancer

Volumn 14, Issue 4, 2011, Pages 269-275

  Lee, Jung Ah ^a   Lee, Hye Yoon ^a   Lee, Eun Sook ^b   Kim, Insun ^c   Bae, Jeoung Won ^a  

^a Korea University College of Medicine   (South Korea)

^b National Cancer Center   (South Korea)

^c Korea University College of Medicine   (South Korea)

Author keywords

Breast neoplasms; Human MicroRNA 21; Oncogene; Prognosis; Survival

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; MICRORNA; MICRORNA 21;

ADULT; ARTICLE; BREAST; BREAST CANCER; BREAST SURGERY; CANCER MORTALITY; CANCER PATIENT; CANCER SURGERY; CANCER TISSUE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOASSAY; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; ONCOGENE; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PATHOPHYSIOLOGY; PROGNOSIS; RISK FACTOR; SURVIVAL RATE; TUMOR VOLUME;

EID: 84863012885     PISSN: 17386756     EISSN: None     Source Type: Journal    
DOI: 10.4048/jbc.2011.14.4.269     Document Type: Article

References (29)

1. Lee RC, Feinbaum RL, Ambros V. Elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993;75:843-54.
2. Lowery AJ, Miller N, McNeill RE, Kerin MJ. McroRNAs as prognostic indicators and therapeutic targets: potential efect on breast cancer management. Clin Cancer Res 2008;14:360-5.
3. Verghese ET, Hanby AM, Speirs V, Hughes TA. Small is beautiful: mi-croRNAs and breast cancer-where are we now? J Pathol 2008;215:214-21.
4. Shi M, Guo N. McroRNA expression and its implications for the diagnosis and therapeutic strategies of breast cancer. Cancer Treat Rev 2009; 35:328-34.
5. Lynam-Lennon N, Maher SG, Reynolds JV. The roles of microRNA in cancer and apoptosis. Biol Rev Camb Philos Soc 2009;84:55-71.
6. Calin GA, Croce CM. McroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-66.
7. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R Sabbioni S, et al. McroRNA gene expression deregulation in human breast cancer. Cancer Res 2005;65:7065-70.
8. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21 -mediated tumor growth. Oncogene 2007;26:2799-803.
9. Qian B, Katsaros D, Lu L, Preti M, Durando A, Arisio R, et al. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. Breast Cancer Res Treat 2009;117:131-40.
10. Yan LX, Huang XF, Shao Q, Huang MY Deng L, Wu QL, et al. McroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008;14:2348-60.
11. Huang GL, Zhang XH, Guo GL, Huang KT, Yang KY, Shen X, et al. Clinical signifcance of miR-21 expression in breast cancer: SYBR-Green I-based real-time RT-PCR study of invasive ductal carcinoma. Oncol Rep 2009;21:673-9.
12. Frankel LB, Christofersen NR Jacobsen A, Lindow M, Krogh A, Lund AH. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem 2008; 283:1026-33.
13. Zhu S, Si ML, Wu H, Mo YY. McroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem 2007;282:14328-36.
14. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010. p.347-76.
15. Yu Z, Baserga R Chen L, Wang C, Lisanti MP Pestell RG. microRNA, cell cycle, and human breast cancer. Am J Pathol 2010; 176:1058-64.
16. Heneghan HM, Mller N, Lowery AJ, Sweeney KJ, Kerin MJ. McroRNAs as novel biomarkers for breast cancer. J Oncol 2009;2009:950201.
17. Zoon CK, Starker EQ, Wilson AM, Emmert-Buck MR, Libutti SK, Tan-grea MA. Current molecular diagnostics of breast cancer and the potential incorporation of microRNA. Expert Rev Mol Diagn 2009;9:455-67.
18. Lankat-Buttgereit B, Göke R. Programmed cell death protein 4 (pdcd4): a novel target for antineoplastic therapy? Biol Cell 2003;95:515-9.
19. Buzdar A. The place of chemotherapy in the treatment of early breast cancer. Br J Cancer 1998;78 Suppl 4:16-20.
20. Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 2008;26:1059-65.
21. Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, et al. Pathologic fndings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 1990;8:103-12.
22. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina. Breast Cancer Study JAMA 2006;295:2492-502.
23. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
24. Lowery AJ, Mller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, et al. McroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res.2009;11:R27.
25. Farragher SM, Tanney A, Kennedy RD, Paul Hark. D RNA expression analysis from formalin fxed parafn embedded tissues. Histochem Cell Biol 2008;130:435-45.
26. Doleshal M, Magotra AA, Choudhury B, Cannon BD, Labourier E, Szafranska AE. Evaluation and validation of total RNA extraction methods for microRNA expression analyses in formalin-fxed, parafn-embedded tissues. J Mol Diagn 2008; 10:203-11.
27. Li J, Smyth P, Flavin R, Cahill S, Denning K, Aherne S, et al. Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotechnol 2007;7:36.
28. Siebolts U, Varnholt H, Drebber U, Dienes HP, Wickenhauser C, Oden-thal M. Tissues from routine pathology archives are suitable for microRNA analyses by quantitative PCR. J Clin Pathol 2009;62:84-8.
29. Hasemeier B, Christgen M, Kreipe H, Lehmann U. Reliable microRNA profling in routinely processed formalin-fxed parafn-embedded breast cancer specimens using fuorescence labelled bead technology. BMC Biotechnol 2008;8:90.